allisartan estearate

Allisartan estearate is a novel, orally administered angiotensin II receptor blocker (ARB) developed in China for the treatment of hypertension. It is a prodrug that, after gastrointestinal absorption, is hydrolyzed by esterases to its active metabolite EXP3174. This metabolite selectively binds to the angiotensin II type 1 (AT1) receptor, blocking the vasoconstrictive and aldosterone-secreting effects of angiotensin II within the renin-angiotensin-aldosterone system (RAAS). Allisartan estearate does not require hepatic metabolism for activation, reducing liver burden compared to other ARBs like losartan. Clinical studies show it effectively lowers blood pressure and reduces cardiovascular events in hypertensive patients, with additional benefits such as lowering uric acid levels and having fewer adverse reactions. It is suitable for long-term use and particularly beneficial for patients with mild hepatic or renal dysfunction or those with hyperuricemia[2][3][4][5].

Brand names

信立坦

Other names

阿利沙坦酯